【摘要】 HR阳性HER2低表达乳腺癌是一种新兴的、热点的治疗亚型，约占所有乳腺癌的53.7%。这类患者往往淋巴结转移率更高，新辅助化疗和传统抗HER2治疗的敏感性可能均较差，探索此类型患者的治疗策略是当前临床亟待解决的难题。HR阳性HER2低表达乳腺癌的治疗策略正在不断更新，包括CDK4/6抑制剂跨线治疗、新一代ADC药物如T-DXd等。随着未来HR阳性HER2低表达乳腺癌更多高级别循证依据的积累，研究数据将为精准诊疗提供更多实践支持，进一步改善HR阳性HER2低表达乳腺癌患者的预后。更多还原

【Abstract】 HR-positive HER2-low breast cancer is a new hotspot therapeutic subtype, accounting for approximately 53.7% of all breast cancers. Patients with this type of cancer tend to have a high rate of lymph node metastasis and poor sensitivity to neoadjuvant chemotherapy and conventional anti-HER2 therapy, and exploring therapeutic strategies for this subtype of patient is a current clinical challenge. Therapeutic strategies for HR-positive HER2-low breast cancer are constantly being updated, including CDK4/6 inhibitors across the lines of therapy, and next-generation antibody-drug conjugates such as T-DXd. With the accumulation of high-level evidence-based evidence for HR-positive HER2-low breast cancer in the future,the research data will provide more practical support for precise diagnosis and treatment, thereby improving the prognosis of patients with HR-positive HER2-low breast cancer.更多还原